The Short-Chain Fatty Acid Butyrate Prevents Gut-Brain Amyloid-Β Pathology and Neuroinflammation in an Alzheimer Mouse Model

Why It Matters

Targeting the gut‑brain axis with butyrate offers a novel, disease‑modifying approach that could complement existing Alzheimer’s therapies and address early peripheral symptoms.

Key Takeaways

• Butyrate reduces gut Aβ accumulation in SAMP8 mice.
• ENS connectivity restored after butyrate treatment.
• Neuroinflammation markers lowered in colon and hippocampus.
• Gut motility and memory performance improved.
• Oral butyrate 4.4 g/L administered for five months.

Pulse Analysis

The traditional view of Alzheimer’s disease as a solely brain‑centric disorder is shifting toward a systemic perspective that includes the gastrointestinal tract. Recent evidence shows that amyloid‑β aggregates not only form plaques in the hippocampus but also accumulate in the enteric nervous system, disrupting neuronal connectivity and causing constipation—an early clinical sign in many patients. This gut‑brain axis creates a feedback loop where peripheral inflammation amplifies central neurodegeneration, highlighting the need for interventions that address both compartments.

Short‑chain fatty acids, particularly butyrate, have emerged as key mediators of gut health. Produced by microbial fermentation of dietary fiber, butyrate fuels colonocytes, reinforces epithelial barrier integrity, and exerts potent anti‑inflammatory effects through histone deacetylase inhibition and modulation of immune signaling pathways. In the SAMP8 mouse study, chronic oral butyrate lowered BACE1 activity, reduced amyloid‑β levels, and attenuated microglial activation in both colon and hippocampus. Restored expression of synaptic proteins such as EphB2 in the ENS correlated with normalized gut motility and improved performance on novel object recognition and Y‑maze tests, underscoring its dual peripheral‑central therapeutic potential.

Translating these findings to humans could reshape Alzheimer’s prevention strategies. Dietary interventions that boost endogenous butyrate production—high‑fiber diets, prebiotic supplementation, or targeted probiotic strains—may offer a low‑risk, scalable approach to modulate the gut microbiome and mitigate disease progression. Ongoing clinical trials are evaluating oral butyrate formulations and microbiome‑based therapies for cognitive decline. Future research should clarify optimal dosing, treatment windows, and biomarkers of gut‑brain response, paving the way for integrated therapies that combine neuroprotective drugs with gut‑focused nutraceuticals.